TTR and amyloidosis: Tafamidis, (TAF, Fig. 1) is a medication used to treat transthyretin-mediated amyloidosis, which is a diverse collection of illnesses that result in end-organ damage due to the extracellular accumulation of insoluble misfolded proteins.1 It is chemically named as 2-(3,5-dichlorophenyl)-benzoxazole-6-carboxylic acid.